Furthermore, tri-specific CAR T cells targeting HER2, IL13Ra2, and EphA2 provide an even more comprehensive coverage of TAs and have been shown to significantly prolong survival of mice bearing GBM patient derived xenografts (Bielamowicz et al., 2018). This evidence concerns the gene IL13RA2 and glioblastoma.